Translate Bio to Present at Jefferies Virtual Healthcare Conference
May 28 2020 - 7:30AM
Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA)
therapeutics company developing a new class of potentially
transformative medicines to treat diseases caused by protein or
gene dysfunction, today announced that Ronald Renaud, chief
executive officer, will participate in a fireside chat at the
Jefferies Virtual Healthcare Conference on Wednesday, June 3,
2020, at 1:00 p.m. ET.
A live webcast of the session will be accessible through the
“Events and Presentations” page of the Company's website at
investors.translate.bio. A replay of the webcast will be archived
on the Translate Bio’s website for 30 days following the
presentation.
About Translate BioTranslate Bio is a
clinical-stage mRNA therapeutics company developing a new class of
potentially transformative medicines to treat diseases caused by
protein or gene dysfunction. Translate Bio is primarily
focused on applying its technology to treat pulmonary diseases
caused by insufficient protein production or where the reduction of
proteins can modify disease. Translate Bio’s lead program is
being developed as a treatment for cystic fibrosis (CF) and is in a
Phase 1/2 clinical trial. The Company also believes its technology
is applicable to a broad range of diseases, including diseases that
affect the liver. Additionally, the platform may be applied to
various classes of treatments, such as therapeutic antibodies or
vaccines in areas such as infectious disease and oncology.
Translate Bio is working with its collaborator Sanofi Pasteur to
develop mRNA vaccines for up to five infectious disease targets and
for COVID-19. For more information about the Company, please visit
www.translate.bio or on Twitter at @TranslateBio.
Contacts for Translate Bio
Investors |
Media |
Teri Dahlman |
Maura Gavaghan |
tdahlman@translate.bio |
mgavaghan@translate.bio |
617-817-8655 |
617-233-1154 |
Telesis Bio (NASDAQ:TBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Telesis Bio (NASDAQ:TBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024